English
English Chinese Simplified Chinese Traditional French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
🇨🇳 LBT at ChinaHospeq 2026 | Connecting with Global Nuclear Medicine Partners in Beijing
Marketing Campaign
News Categories
Featured News
LBT LB-20 Medical Cyclotron Supports Clinical PET Imaging and Radiopharmaceutical Research in Xi’an, China
LBT LB-20 Medical Cyclotron Supports ...
What Makes RDC Development So Challenging? From Molecular Design to Cyclotron Radionuclide Production
What Makes RDC Development So Challen...
Expanding PET Radiopharmaceutical Production in Burkina Faso with an LBT 11 MeV Medical Cyclotron
Expanding PET Radiopharmaceutical Pro...
RDC vs ADC: What Makes Radionuclides a Unique Therapeutic Payload? 🎯 ADC and RDC share a similar idea: use a targeting molecule to find the tumor, then let the payload do the killing. But their thera
RDC vs ADC: What Makes Radionuclides ...
Beyond ¹⁷⁷Lu and ²²⁵Ac: Where Are Next-Generation Therapeutic Radionuclides Heading?
Beyond ¹⁷⁷Lu and ²²⁵Ac: Where Are Nex...
β vs α: Why Are There Two Different Routes in Radionuclide Therapy?
β vs α: Why Are There Two Different R...
Why Do Diagnostic and Therapeutic Radionuclides Need to Be Matched?
Why Do Diagnostic and Therapeutic Rad...
From Imaging to Therapy: How Radioactive Decay Shapes Clinical Use
From Imaging to Therapy: How Radioact...
From Seeing Disease to Treating It: Why Radiopharmaceuticals Matter
From Seeing Disease to Treating It: W...
🧪 When a Pharmaceutical Company Builds Its Own Radionuclide Production Capability
🧪 When a Pharmaceutical Company Build...
0102030405

🇨🇳 LBT at ChinaHospeq 2026 | Connecting with Global Nuclear Medicine Partners in Beijing

2026-08-21
From August 14–16, LBT participated in ChinaHospeq 2026 at the National Convention Center in Beijing, showcasing our medical cyclotron technologies and integrated solutions for nuclear medicine.
At the exhibition, LBT presented the LB-11MTS 11 MeV medical cyclotron, highlighting our capabilities across medical cyclotrons, isotope production, radiopharmaceutical preparation, and complete nuclear medicine center solutions.
🌍 During the three-day event, we welcomed customers and partners from Russia, Central Asia, Myanmar, Bangladesh, Latin America, and other markets. Discussions focused on practical project needs, including cyclotron selection, isotope production capacity, radiopharmaceutical production systems, facility planning, and technical services.
The LB-11MTS, with its capabilities for clinical PET applications and expansion into multi-isotope production, attracted particular interest from international visitors. Our team also discussed tailored configurations based on different patient volumes, isotope requirements, site conditions, and future development plans.
🤝 ChinaHospeq 2026 provided another valuable opportunity for LBT to strengthen connections with partners across multiple international markets.
Building on nearly 20 years of experience in advanced radiation source R&D, LBT will continue advancing independent innovation, expanding our global presence, and strengthening localized service capabilities to deliver reliable and efficient nuclear medicine solutions worldwide.